Video

Dr. Bauml Discusses Liquid Biopsies in Lung Cancer

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the role of liquid biopsies for patients with lung cancer.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the role of liquid biopsies for patients with lung cancer.

Liquid biopsies are used by clinicians to look for a wide variety of resistance mutations when giving a targeted therapy. According to Bauml, as we expand liquid biopsies, it is going to be possible to assess tumor mutational burden, leading to better decisions regarding immunotherapy, explains Bauml.

A retrospective analysis of a randomized study determined that a liquid biopsy that measures tumor mutational burden showed promise as an aid for predicting benefit in patients with lung cancer treated with a checkpoint inhibitor. Tumor mutation burden in blood ≥16 had a significant association with improved progression-free survival in patients treated with the PD-L1 inhibitor atezolizumab (Tecentriq).

There was an additional study that looked at patients who had a resection of their lung cancer, and liquid biopsies were used to follow those patients to determine when the relapse would occur. The other role for liquid biopsies is to monitor those patients to watch the genetic landscape.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity